SCYNEXIS, Inc. (SCYX) 10-Year Financial Performance & Capital Metrics

SCYX • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsInfectious Disease Therapeutics

AboutSCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.Show more

Revenue $4M -97.3%
EBITDA -$35M -148.3%
Net Income -$21M -131.8%
EPS (Diluted) -0.44 -131.7%
Gross Margin 100% +12.5%
EBITDA Margin -944.77% -1907.5%
Operating Margin -990.84% -2010.8%
Net Margin -568.29% -1287.9%
ROE -33.25% -118.9%
ROIC -50.94% -128.0%
Debt/Equity 0.30 +42.9%
Interest Coverage -14.53 -222.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 98.7%
✓Trading at only 0.6x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y11.55%

5Y98.68%

3Y-34.22%

TTM-65.77%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM30.57%

EPS CAGR

10Y-

5Y-

3Y-

TTM30.71%

ROCE

10Y Avg-57.38%

5Y Avg-41.89%

3Y Avg-19.68%

Latest-41.55%

Peer Comparison

Infectious Disease Therapeutics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
SIGASIGA Technologies, Inc.	473.35M	6.61	7.96	-0.86%	43.23%	36.6%	10.29%	0.00
SCYXSCYNEXIS, Inc.	26.94M	0.64	-1.46	-97.33%	-8.63%	-69.45%		0.30

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	257K	257K	257K	257K	121K	0	13.16M	5.09M	140.14M	3.75M
Revenue Growth %	-0.8%	0%	0%	0%	-0.53%	-1%	-	-0.61%	26.53%	-0.97%
Cost of Goods Sold+	0	0	0	0	0	303K	312K	628K	15.62M	0
COGS % of Revenue	-	-	-	-	-	-	0.02%	0.12%	0.11%	-
Gross Profit+	257K	257K	257K	257K	121K	-303K	12.85M	4.46M	124.52M	3.75M
Gross Margin %	1%	1%	1%	1%	1%	-	0.98%	0.88%	0.89%	1%
Gross Profit Growth %	1.02%	0%	0%	0%	-0.53%	-3.5%	43.41%	-0.65%	26.9%	-0.97%
Operating Expenses+	28.61M	28.07M	26.58M	30.24M	49.04M	50.85M	73.69M	90.22M	51.85M	40.86M
OpEx % of Revenue	111.31%	109.24%	103.41%	117.67%	405.31%	-	5.6%	17.72%	0.37%	10.91%
Selling, General & Admin	12.17M	8M	8.25M	8.68M	10.65M	14.32M	49.92M	62.96M	20.92M	14.46M
SG&A % of Revenue	47.34%	31.12%	32.11%	33.77%	88%	-	3.79%	12.37%	0.15%	3.86%
Research & Development	16.44M	20.08M	18.33M	21.56M	38.39M	36.52M	23.77M	27.26M	30.93M	26.41M
R&D % of Revenue	63.97%	78.12%	71.31%	83.89%	317.31%	-	1.81%	5.35%	0.22%	7.05%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-28.35M	-27.82M	-26.32M	-29.98M	-48.92M	-51.15M	-60.84M	-85.76M	72.67M	-37.12M
Operating Margin %	-110.31%	-108.24%	-102.41%	-116.67%	-404.31%	-	-4.62%	-16.84%	0.52%	-9.91%
Operating Income Growth %	-0.94%	0.02%	0.05%	-0.14%	-0.63%	-0.05%	-0.19%	-0.41%	1.85%	-1.51%
EBITDA+	-27.9M	-27.79M	-26.28M	-29.93M	-48.64M	-50.85M	-60.46M	-84.94M	73.25M	-35.39M
EBITDA Margin %	-108.57%	-108.14%	-102.25%	-116.46%	-401.95%	-	-4.59%	-16.69%	0.52%	-9.45%
EBITDA Growth %	-1.08%	0%	0.05%	-0.14%	-0.62%	-0.05%	-0.19%	-0.4%	1.86%	-1.48%
D&A (Non-Cash Add-back)	447K	26K	41K	53K	285K	303K	379K	813K	580K	1.73M
EBIT	-28.35M	-29.54M	-23.2M	-17.15M	-51.55M	-55.95M	-33.29M	-60.72M	70.31M	-20.31M
Net Interest Income+	11K	-266K	-1.47M	-1.09M	-1.35M	-992K	-3.94M	-5.37M	-2.17M	1.74M
Interest Income	0	185K	386K	967K	805K	189K	24K	1.42M	3.95M	4.29M
Interest Expense	11K	451K	1.85M	2.05M	2.16M	1.18M	3.96M	6.79M	6.12M	2.55M
Other Income/Expense	11K	-2.17M	1.26M	10.78M	-4.79M	-7.18M	24.88M	18.25M	-5.49M	15.98M
Pretax Income+	-28.34M	-29.99M	-25.06M	-19.2M	-53.71M	-58.33M	-35.95M	-67.51M	67.18M	-21.14M
Pretax Margin %	-110.26%	-116.69%	-97.51%	-74.72%	-443.88%	-	-2.73%	-13.26%	0.48%	-5.64%
Income Tax+	0	0	0	-6.74M	0	-3.15M	-3.09M	-4.7M	138K	151K
Effective Tax Rate %	1.15%	1%	1%	0.65%	1%	0.95%	0.91%	0.93%	1%	1.01%
Net Income+	-32.62M	-29.99M	-25.06M	-12.47M	-53.71M	-55.19M	-32.87M	-62.81M	67.04M	-21.29M
Net Margin %	-126.94%	-116.69%	-97.51%	-48.51%	-443.88%	-	-2.5%	-12.34%	0.48%	-5.68%
Net Income Growth %	-6.71%	0.08%	0.16%	0.5%	-3.31%	-0.03%	0.4%	-0.91%	2.07%	-1.32%
Net Income (Continuing)	-28.34M	-29.99M	-25.06M	-12.47M	-53.71M	-55.19M	-32.87M	-62.81M	67.04M	-21.29M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-26.82	-15.75	-9.37	-2.84	-9.85	-5.15	-1.25	-1.47	1.39	-0.44
EPS Growth %	-2.76%	0.41%	0.41%	0.7%	-2.47%	0.48%	0.76%	-0.18%	1.95%	-1.32%
EPS (Basic)	-26.82	-15.75	-9.37	-2.84	-9.85	-5.15	-1.25	-1.47	1.40	-0.44
Diluted Shares Outstanding	1.22M	1.9M	2.67M	4.39M	5.61M	10.72M	26.38M	42.61M	48.39M	48.51M
Basic Shares Outstanding	1.22M	1.9M	2.67M	4.39M	5.61M	10.72M	26.38M	42.61M	47.85M	48.51M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	48.44M	59.33M	44.96M	51.46M	52.4M	98.21M	109.38M	79.06M	102.12M	72.18M
Cash & Short-Term Investments	46.98M	58.59M	43.89M	44.16M	48.41M	93.04M	104.48M	73.5M	74.36M	59.3M
Cash Only	46.98M	35.66M	11.47M	11.44M	41.92M	93.04M	104.48M	45.81M	34.05M	16.05M
Short-Term Investments	0	22.93M	32.42M	32.72M	6.49M	0	0	27.69M	40.31M	43.25M
Accounts Receivable	930K	233K	251K	6.73M	0	2.88M	861K	2.1M	21.83M	10.26M
Days Sales Outstanding	1.32K	330.91	356.48	9.56K	-	-	23.87	150.63	56.85	999.9
Inventory	484K	467K	725K	520K	0	0	463K	899K	0	0
Days Inventory Outstanding	-	-	-	-	-	-	541.65	522.51	-	-
Other Current Assets	38K	41K	91K	109K	674K	373K	4K	117K	5.29M	1.67M
Total Non-Current Assets+	836K	465K	890K	1.71M	4.75M	4.33M	10.46M	8.75M	26.3M	18.46M
Property, Plant & Equipment	0	0	4K	516K	3.6M	3.3M	2.91M	2.59M	2.36M	2.09M
Fixed Asset Turnover	-	-	64.25x	0.50x	0.03x	-	4.52x	1.96x	59.28x	1.79x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	1.06M	408K	0	0
Long-Term Investments	0	0	0	273K	0	0	218K	163K	23.59M	15.85M
Other Non-Current Assets	836K	465K	886K	918K	1.16M	1.03M	6.49M	5.75M	338K	526K
Total Assets+	49.27M	59.79M	45.85M	53.17M	57.15M	102.54M	119.84M	87.81M	128.41M	90.64M
Asset Turnover	0.01x	0.00x	0.01x	0.00x	0.00x	-	0.11x	0.06x	1.09x	0.04x
Asset Growth %	0.24%	0.21%	-0.23%	0.16%	0.07%	0.79%	0.17%	-0.27%	0.46%	-0.29%
Total Current Liabilities+	6.66M	3.72M	10.14M	5.88M	11.01M	26.4M	13.62M	17.62M	16.3M	24.1M
Accounts Payable	619K	2.19M	3.83M	3.65M	7.18M	4.64M	7.85M	5.94M	7.15M	4.57M
Days Payables Outstanding	-	-	-	-	-	5.59K	9.18K	3.45K	167.01	-
Short-Term Debt	0	0	4.35M	0	0	0	70K	0	0	13.69M
Deferred Revenue (Current)	257K	257K	257K	121K	0	0	0	0	1000K	1000K
Other Current Liabilities	4.97M	516K	913K	885K	1.8M	19.75M	3.62M	5.77M	1.83M	1.76M
Current Ratio	7.27x	15.96x	4.43x	8.76x	4.76x	3.72x	8.03x	4.49x	6.26x	3.00x
Quick Ratio	7.20x	15.84x	4.36x	8.67x	4.76x	3.72x	8.00x	4.44x	6.26x	3.00x
Cash Conversion Cycle	-	-	-	-	-	-	-8.62K	-2.78K	-	-
Total Non-Current Liabilities+	660K	21.26M	14.3M	16.07M	33.24M	53.38M	64.96M	66.96M	39.15M	11.47M
Long-Term Debt	0	14.25M	10.3M	15.08M	11.52M	16.52M	40.35M	45.39M	12.16M	0
Capital Lease Obligations	0	0	0	0	3.33M	3.27M	3.2M	2.92M	2.58M	2.17M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	25K	6.63M	3.87M	986K	18.4M	33.59M	21.41M	18.64M	21.68M	8M
Total Liabilities	7.32M	24.97M	24.44M	21.95M	44.26M	79.78M	78.58M	84.58M	55.45M	35.57M
Total Debt+	0	14.25M	14.65M	15.08M	14.88M	19.84M	43.63M	48.6M	15.08M	16.27M
Net Debt	-46.98M	-21.4M	3.18M	3.64M	-27.04M	-73.2M	-60.86M	2.78M	-18.97M	219K
Debt / Equity	-	0.41x	0.68x	0.48x	1.15x	0.87x	1.06x	15.03x	0.21x	0.30x
Debt / EBITDA	-	-	-	-	-	-	-	-	0.21x	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-0.26x	-
Interest Coverage	-2577.18x	-61.68x	-14.19x	-14.60x	-22.68x	-43.31x	-15.35x	-12.64x	11.87x	-14.53x
Total Equity+	41.95M	34.82M	21.41M	31.23M	12.89M	22.76M	41.26M	3.23M	72.96M	55.08M
Equity Growth %	0.25%	-0.17%	-0.39%	0.46%	-0.59%	0.76%	0.81%	-0.92%	21.57%	-0.25%
Book Value per Share	34.49	18.29	8.00	7.12	2.30	2.12	1.56	0.08	1.51	1.14
Total Shareholders' Equity	41.95M	34.82M	21.41M	31.23M	12.89M	22.76M	41.26M	3.23M	72.96M	55.08M
Common Stock	14K	24K	29K	48K	10K	20K	32K	36K	40K	41K
Retained Earnings	-150.13M	-180.12M	-205.25M	-217.72M	-271.43M	-326.61M	-359.48M	-422.29M	-355.25M	-376.54M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	-61K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-24.55M	-29.35M	-24.56M	-28.32M	-38.12M	-49.35M	-54.56M	-79.88M	60.16M	-24.01M
Operating CF Margin %	-95.51%	-114.21%	-95.55%	-110.21%	-315.03%	-	-4.14%	-15.69%	0.43%	-6.41%
Operating CF Growth %	-1.59%	-0.2%	0.16%	-0.15%	-0.35%	-0.29%	-0.11%	-0.46%	1.75%	-1.4%
Net Income	-32.62M	-29.99M	-25.06M	-12.47M	-53.71M	-55.19M	-32.87M	-62.81M	67.04M	-21.29M
Depreciation & Amortization	447K	26K	41K	53K	111K	111K	379K	606K	580K	1.73M
Stock-Based Compensation	3.02M	1.21M	1.66M	1.82M	1.83M	2.22M	2.09M	3.69M	2.62M	3.35M
Deferred Taxes	659K	2.33M	-2.6M	-11.75M	3.96M	0	0	0	0	0
Other Non-Cash Items	-108K	101K	375K	424K	1.34M	6.72M	-27.31M	-22.13M	20.56M	-15.08M
Working Capital Changes	4.06M	-3.03M	1.03M	-6.4M	8.35M	-3.22M	3.15M	764K	-30.64M	7.28M
Change in Receivables	31K	0	0	0	0	0	-861K	-1.24M	-19.73M	11.56M
Change in Inventory	2.01M	0	0	0	0	0	-5.29M	-436K	-8.85M	0
Change in Payables	1.07M	-309K	2.08M	223K	5.21M	-2.6M	2.76M	-1.48M	1.17M	-2.65M
Cash from Investing+	1.59M	-22.47M	-9.62M	-803K	26.24M	6.47M	-1.17M	-27.39M	-34.88M	6.15M
Capital Expenditures	-589K	-27K	-2K	-565K	0	-4K	-1.17M	-9K	0	0
CapEx % of Revenue	2.29%	0.11%	0.01%	2.2%	-	-	0.09%	0%	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-74K	-22.45M	-9.62M	-238K	0	0	0	0	0	0
Cash from Financing+	37.7M	40.5M	9.99M	29.42M	42.3M	94M	67.12M	48.6M	-36.72M	-139K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-3.7M	-2.58M	-298K	-2.23M	-1.25M	-5.85M	-1.44M	-26K	-93K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-25.13M	-29.38M	-24.56M	-28.89M	-38.12M	-49.36M	-55.73M	-79.89M	60.16M	-24.01M
FCF Margin %	-97.8%	-114.32%	-95.56%	-112.4%	-315.03%	-	-4.23%	-15.69%	0.43%	-6.41%
FCF Growth %	-1.47%	-0.17%	0.16%	-0.18%	-0.32%	-0.29%	-0.13%	-0.43%	1.75%	-1.4%
FCF per Share	-20.66	-15.43	-9.18	-6.58	-6.80	-4.60	-2.11	-1.87	1.24	-0.49
FCF Conversion (FCF/Net Income)	0.75x	0.98x	0.98x	2.27x	0.71x	0.89x	1.66x	1.27x	0.90x	1.13x
Interest Paid	0	0	0	0	0	1.09M	2.25M	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-86.56%	-78.13%	-89.14%	-47.38%	-243.47%	-309.57%	-102.68%	-282.34%	175.97%	-33.25%
Return on Invested Capital (ROIC)	-	-497.98%	-103.87%	-75.64%	-354.04%	-	-	-1069.11%	181.65%	-50.94%
Gross Margin	100%	100%	100%	100%	100%	-	97.63%	87.66%	88.85%	100%
Net Margin	-12693.77%	-11668.87%	-9750.97%	-4851.36%	-44388.43%	-	-249.68%	-1233.73%	47.84%	-568.29%
Debt / Equity	-	0.41x	0.68x	0.48x	1.15x	0.87x	1.06x	15.03x	0.21x	0.30x
Interest Coverage	-2577.18x	-61.68x	-14.19x	-14.60x	-22.68x	-43.31x	-15.35x	-12.64x	11.87x	-14.53x
FCF Conversion	0.75x	0.98x	0.98x	2.27x	0.71x	0.89x	1.66x	1.27x	0.90x	1.13x
Revenue Growth	-79.54%	0%	0%	0%	-52.92%	-100%	-	-61.32%	2652.72%	-97.33%

Revenue by Segment

	2014	2015	2016	2018	2019	2021	2022	2023	2024
License and Service	-	-	-	-	-	-	103K	139.1M	3.75M
License and Service Growth	-	-	-	-	-	-	-	134945.63%	-97.31%
Product	-	-	-	-	-	1.11M	4.99M	1.04M	-
Product Growth	-	-	-	-	-	-	348.16%	-79.07%	-
License And Service	-	-	-	300K	100K	12.05M	-	-	-
License And Service Growth	-	-	-	-	-66.67%	11950.00%	-	-	-

Revenue by Geography

	2014	2015	2016	2018	2019	2021	2022	2023	2024
Other Non-US	1.37M	257K	257K	-	-	-	-	-	-
Other Non-US Growth	-	-81.20%	0.00%	-	-	-	-	-	-
UNITED STATES	16.42M	6.93M	-	-	-	-	-	-	-
UNITED STATES Growth	-	-57.79%	-	-	-	-	-	-	-
Europe	1.24M	477K	-	-	-	-	-	-	-
Europe Growth	-	-61.38%	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

SCYNEXIS, Inc. (SCYX) reported $2.9M in revenue for fiscal year 2024. This represents a 83% decrease from $16.8M in 2012.

SCYNEXIS, Inc. (SCYX) saw revenue decline by 97.3% over the past year.

SCYNEXIS, Inc. (SCYX) reported a net loss of $25.3M for fiscal year 2024.

Dividend & Returns

SCYNEXIS, Inc. (SCYX) has a return on equity (ROE) of -33.3%. Negative ROE indicates the company is unprofitable.

SCYNEXIS, Inc. (SCYX) had negative free cash flow of $33.6M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

SCYNEXIS, Inc. (SCYX) 10-Year Financial Performance & Capital Metrics

SCYX • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsInfectious Disease Therapeutics

Revenue $4M -97.3%
EBITDA -$35M -148.3%
Net Income -$21M -131.8%
EPS (Diluted) -0.44 -131.7%
Gross Margin 100% +12.5%
EBITDA Margin -944.77% -1907.5%
Operating Margin -990.84% -2010.8%
Net Margin -568.29% -1287.9%
ROE -33.25% -118.9%
ROIC -50.94% -128.0%
Debt/Equity 0.30 +42.9%
Interest Coverage -14.53 -222.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 98.7%
✓Trading at only 0.6x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y11.55%

5Y98.68%

3Y-34.22%

TTM-65.77%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM30.57%

EPS CAGR

10Y-

5Y-

3Y-

TTM30.71%

ROCE

10Y Avg-57.38%

5Y Avg-41.89%

3Y Avg-19.68%

Latest-41.55%

Peer Comparison

Infectious Disease Therapeutics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
SIGASIGA Technologies, Inc.	473.35M	6.61	7.96	-0.86%	43.23%	36.6%	10.29%	0.00
SCYXSCYNEXIS, Inc.	26.94M	0.64	-1.46	-97.33%	-8.63%	-69.45%		0.30

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	257K	257K	257K	257K	121K	0	13.16M	5.09M	140.14M	3.75M
Revenue Growth %	-0.8%	0%	0%	0%	-0.53%	-1%	-	-0.61%	26.53%	-0.97%
Cost of Goods Sold+	0	0	0	0	0	303K	312K	628K	15.62M	0
COGS % of Revenue	-	-	-	-	-	-	0.02%	0.12%	0.11%	-
Gross Profit+	257K	257K	257K	257K	121K	-303K	12.85M	4.46M	124.52M	3.75M
Gross Margin %	1%	1%	1%	1%	1%	-	0.98%	0.88%	0.89%	1%
Gross Profit Growth %	1.02%	0%	0%	0%	-0.53%	-3.5%	43.41%	-0.65%	26.9%	-0.97%
Operating Expenses+	28.61M	28.07M	26.58M	30.24M	49.04M	50.85M	73.69M	90.22M	51.85M	40.86M
OpEx % of Revenue	111.31%	109.24%	103.41%	117.67%	405.31%	-	5.6%	17.72%	0.37%	10.91%
Selling, General & Admin	12.17M	8M	8.25M	8.68M	10.65M	14.32M	49.92M	62.96M	20.92M	14.46M
SG&A % of Revenue	47.34%	31.12%	32.11%	33.77%	88%	-	3.79%	12.37%	0.15%	3.86%
Research & Development	16.44M	20.08M	18.33M	21.56M	38.39M	36.52M	23.77M	27.26M	30.93M	26.41M
R&D % of Revenue	63.97%	78.12%	71.31%	83.89%	317.31%	-	1.81%	5.35%	0.22%	7.05%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-28.35M	-27.82M	-26.32M	-29.98M	-48.92M	-51.15M	-60.84M	-85.76M	72.67M	-37.12M
Operating Margin %	-110.31%	-108.24%	-102.41%	-116.67%	-404.31%	-	-4.62%	-16.84%	0.52%	-9.91%
Operating Income Growth %	-0.94%	0.02%	0.05%	-0.14%	-0.63%	-0.05%	-0.19%	-0.41%	1.85%	-1.51%
EBITDA+	-27.9M	-27.79M	-26.28M	-29.93M	-48.64M	-50.85M	-60.46M	-84.94M	73.25M	-35.39M
EBITDA Margin %	-108.57%	-108.14%	-102.25%	-116.46%	-401.95%	-	-4.59%	-16.69%	0.52%	-9.45%
EBITDA Growth %	-1.08%	0%	0.05%	-0.14%	-0.62%	-0.05%	-0.19%	-0.4%	1.86%	-1.48%
D&A (Non-Cash Add-back)	447K	26K	41K	53K	285K	303K	379K	813K	580K	1.73M
EBIT	-28.35M	-29.54M	-23.2M	-17.15M	-51.55M	-55.95M	-33.29M	-60.72M	70.31M	-20.31M
Net Interest Income+	11K	-266K	-1.47M	-1.09M	-1.35M	-992K	-3.94M	-5.37M	-2.17M	1.74M
Interest Income	0	185K	386K	967K	805K	189K	24K	1.42M	3.95M	4.29M
Interest Expense	11K	451K	1.85M	2.05M	2.16M	1.18M	3.96M	6.79M	6.12M	2.55M
Other Income/Expense	11K	-2.17M	1.26M	10.78M	-4.79M	-7.18M	24.88M	18.25M	-5.49M	15.98M
Pretax Income+	-28.34M	-29.99M	-25.06M	-19.2M	-53.71M	-58.33M	-35.95M	-67.51M	67.18M	-21.14M
Pretax Margin %	-110.26%	-116.69%	-97.51%	-74.72%	-443.88%	-	-2.73%	-13.26%	0.48%	-5.64%
Income Tax+	0	0	0	-6.74M	0	-3.15M	-3.09M	-4.7M	138K	151K
Effective Tax Rate %	1.15%	1%	1%	0.65%	1%	0.95%	0.91%	0.93%	1%	1.01%
Net Income+	-32.62M	-29.99M	-25.06M	-12.47M	-53.71M	-55.19M	-32.87M	-62.81M	67.04M	-21.29M
Net Margin %	-126.94%	-116.69%	-97.51%	-48.51%	-443.88%	-	-2.5%	-12.34%	0.48%	-5.68%
Net Income Growth %	-6.71%	0.08%	0.16%	0.5%	-3.31%	-0.03%	0.4%	-0.91%	2.07%	-1.32%
Net Income (Continuing)	-28.34M	-29.99M	-25.06M	-12.47M	-53.71M	-55.19M	-32.87M	-62.81M	67.04M	-21.29M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-26.82	-15.75	-9.37	-2.84	-9.85	-5.15	-1.25	-1.47	1.39	-0.44
EPS Growth %	-2.76%	0.41%	0.41%	0.7%	-2.47%	0.48%	0.76%	-0.18%	1.95%	-1.32%
EPS (Basic)	-26.82	-15.75	-9.37	-2.84	-9.85	-5.15	-1.25	-1.47	1.40	-0.44
Diluted Shares Outstanding	1.22M	1.9M	2.67M	4.39M	5.61M	10.72M	26.38M	42.61M	48.39M	48.51M
Basic Shares Outstanding	1.22M	1.9M	2.67M	4.39M	5.61M	10.72M	26.38M	42.61M	47.85M	48.51M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	48.44M	59.33M	44.96M	51.46M	52.4M	98.21M	109.38M	79.06M	102.12M	72.18M
Cash & Short-Term Investments	46.98M	58.59M	43.89M	44.16M	48.41M	93.04M	104.48M	73.5M	74.36M	59.3M
Cash Only	46.98M	35.66M	11.47M	11.44M	41.92M	93.04M	104.48M	45.81M	34.05M	16.05M
Short-Term Investments	0	22.93M	32.42M	32.72M	6.49M	0	0	27.69M	40.31M	43.25M
Accounts Receivable	930K	233K	251K	6.73M	0	2.88M	861K	2.1M	21.83M	10.26M
Days Sales Outstanding	1.32K	330.91	356.48	9.56K	-	-	23.87	150.63	56.85	999.9
Inventory	484K	467K	725K	520K	0	0	463K	899K	0	0
Days Inventory Outstanding	-	-	-	-	-	-	541.65	522.51	-	-
Other Current Assets	38K	41K	91K	109K	674K	373K	4K	117K	5.29M	1.67M
Total Non-Current Assets+	836K	465K	890K	1.71M	4.75M	4.33M	10.46M	8.75M	26.3M	18.46M
Property, Plant & Equipment	0	0	4K	516K	3.6M	3.3M	2.91M	2.59M	2.36M	2.09M
Fixed Asset Turnover	-	-	64.25x	0.50x	0.03x	-	4.52x	1.96x	59.28x	1.79x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	1.06M	408K	0	0
Long-Term Investments	0	0	0	273K	0	0	218K	163K	23.59M	15.85M
Other Non-Current Assets	836K	465K	886K	918K	1.16M	1.03M	6.49M	5.75M	338K	526K
Total Assets+	49.27M	59.79M	45.85M	53.17M	57.15M	102.54M	119.84M	87.81M	128.41M	90.64M
Asset Turnover	0.01x	0.00x	0.01x	0.00x	0.00x	-	0.11x	0.06x	1.09x	0.04x
Asset Growth %	0.24%	0.21%	-0.23%	0.16%	0.07%	0.79%	0.17%	-0.27%	0.46%	-0.29%
Total Current Liabilities+	6.66M	3.72M	10.14M	5.88M	11.01M	26.4M	13.62M	17.62M	16.3M	24.1M
Accounts Payable	619K	2.19M	3.83M	3.65M	7.18M	4.64M	7.85M	5.94M	7.15M	4.57M
Days Payables Outstanding	-	-	-	-	-	5.59K	9.18K	3.45K	167.01	-
Short-Term Debt	0	0	4.35M	0	0	0	70K	0	0	13.69M
Deferred Revenue (Current)	257K	257K	257K	121K	0	0	0	0	1000K	1000K
Other Current Liabilities	4.97M	516K	913K	885K	1.8M	19.75M	3.62M	5.77M	1.83M	1.76M
Current Ratio	7.27x	15.96x	4.43x	8.76x	4.76x	3.72x	8.03x	4.49x	6.26x	3.00x
Quick Ratio	7.20x	15.84x	4.36x	8.67x	4.76x	3.72x	8.00x	4.44x	6.26x	3.00x
Cash Conversion Cycle	-	-	-	-	-	-	-8.62K	-2.78K	-	-
Total Non-Current Liabilities+	660K	21.26M	14.3M	16.07M	33.24M	53.38M	64.96M	66.96M	39.15M	11.47M
Long-Term Debt	0	14.25M	10.3M	15.08M	11.52M	16.52M	40.35M	45.39M	12.16M	0
Capital Lease Obligations	0	0	0	0	3.33M	3.27M	3.2M	2.92M	2.58M	2.17M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	25K	6.63M	3.87M	986K	18.4M	33.59M	21.41M	18.64M	21.68M	8M
Total Liabilities	7.32M	24.97M	24.44M	21.95M	44.26M	79.78M	78.58M	84.58M	55.45M	35.57M
Total Debt+	0	14.25M	14.65M	15.08M	14.88M	19.84M	43.63M	48.6M	15.08M	16.27M
Net Debt	-46.98M	-21.4M	3.18M	3.64M	-27.04M	-73.2M	-60.86M	2.78M	-18.97M	219K
Debt / Equity	-	0.41x	0.68x	0.48x	1.15x	0.87x	1.06x	15.03x	0.21x	0.30x
Debt / EBITDA	-	-	-	-	-	-	-	-	0.21x	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-0.26x	-
Interest Coverage	-2577.18x	-61.68x	-14.19x	-14.60x	-22.68x	-43.31x	-15.35x	-12.64x	11.87x	-14.53x
Total Equity+	41.95M	34.82M	21.41M	31.23M	12.89M	22.76M	41.26M	3.23M	72.96M	55.08M
Equity Growth %	0.25%	-0.17%	-0.39%	0.46%	-0.59%	0.76%	0.81%	-0.92%	21.57%	-0.25%
Book Value per Share	34.49	18.29	8.00	7.12	2.30	2.12	1.56	0.08	1.51	1.14
Total Shareholders' Equity	41.95M	34.82M	21.41M	31.23M	12.89M	22.76M	41.26M	3.23M	72.96M	55.08M
Common Stock	14K	24K	29K	48K	10K	20K	32K	36K	40K	41K
Retained Earnings	-150.13M	-180.12M	-205.25M	-217.72M	-271.43M	-326.61M	-359.48M	-422.29M	-355.25M	-376.54M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	-61K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-24.55M	-29.35M	-24.56M	-28.32M	-38.12M	-49.35M	-54.56M	-79.88M	60.16M	-24.01M
Operating CF Margin %	-95.51%	-114.21%	-95.55%	-110.21%	-315.03%	-	-4.14%	-15.69%	0.43%	-6.41%
Operating CF Growth %	-1.59%	-0.2%	0.16%	-0.15%	-0.35%	-0.29%	-0.11%	-0.46%	1.75%	-1.4%
Net Income	-32.62M	-29.99M	-25.06M	-12.47M	-53.71M	-55.19M	-32.87M	-62.81M	67.04M	-21.29M
Depreciation & Amortization	447K	26K	41K	53K	111K	111K	379K	606K	580K	1.73M
Stock-Based Compensation	3.02M	1.21M	1.66M	1.82M	1.83M	2.22M	2.09M	3.69M	2.62M	3.35M
Deferred Taxes	659K	2.33M	-2.6M	-11.75M	3.96M	0	0	0	0	0
Other Non-Cash Items	-108K	101K	375K	424K	1.34M	6.72M	-27.31M	-22.13M	20.56M	-15.08M
Working Capital Changes	4.06M	-3.03M	1.03M	-6.4M	8.35M	-3.22M	3.15M	764K	-30.64M	7.28M
Change in Receivables	31K	0	0	0	0	0	-861K	-1.24M	-19.73M	11.56M
Change in Inventory	2.01M	0	0	0	0	0	-5.29M	-436K	-8.85M	0
Change in Payables	1.07M	-309K	2.08M	223K	5.21M	-2.6M	2.76M	-1.48M	1.17M	-2.65M
Cash from Investing+	1.59M	-22.47M	-9.62M	-803K	26.24M	6.47M	-1.17M	-27.39M	-34.88M	6.15M
Capital Expenditures	-589K	-27K	-2K	-565K	0	-4K	-1.17M	-9K	0	0
CapEx % of Revenue	2.29%	0.11%	0.01%	2.2%	-	-	0.09%	0%	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-74K	-22.45M	-9.62M	-238K	0	0	0	0	0	0
Cash from Financing+	37.7M	40.5M	9.99M	29.42M	42.3M	94M	67.12M	48.6M	-36.72M	-139K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-3.7M	-2.58M	-298K	-2.23M	-1.25M	-5.85M	-1.44M	-26K	-93K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-25.13M	-29.38M	-24.56M	-28.89M	-38.12M	-49.36M	-55.73M	-79.89M	60.16M	-24.01M
FCF Margin %	-97.8%	-114.32%	-95.56%	-112.4%	-315.03%	-	-4.23%	-15.69%	0.43%	-6.41%
FCF Growth %	-1.47%	-0.17%	0.16%	-0.18%	-0.32%	-0.29%	-0.13%	-0.43%	1.75%	-1.4%
FCF per Share	-20.66	-15.43	-9.18	-6.58	-6.80	-4.60	-2.11	-1.87	1.24	-0.49
FCF Conversion (FCF/Net Income)	0.75x	0.98x	0.98x	2.27x	0.71x	0.89x	1.66x	1.27x	0.90x	1.13x
Interest Paid	0	0	0	0	0	1.09M	2.25M	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-86.56%	-78.13%	-89.14%	-47.38%	-243.47%	-309.57%	-102.68%	-282.34%	175.97%	-33.25%
Return on Invested Capital (ROIC)	-	-497.98%	-103.87%	-75.64%	-354.04%	-	-	-1069.11%	181.65%	-50.94%
Gross Margin	100%	100%	100%	100%	100%	-	97.63%	87.66%	88.85%	100%
Net Margin	-12693.77%	-11668.87%	-9750.97%	-4851.36%	-44388.43%	-	-249.68%	-1233.73%	47.84%	-568.29%
Debt / Equity	-	0.41x	0.68x	0.48x	1.15x	0.87x	1.06x	15.03x	0.21x	0.30x
Interest Coverage	-2577.18x	-61.68x	-14.19x	-14.60x	-22.68x	-43.31x	-15.35x	-12.64x	11.87x	-14.53x
FCF Conversion	0.75x	0.98x	0.98x	2.27x	0.71x	0.89x	1.66x	1.27x	0.90x	1.13x
Revenue Growth	-79.54%	0%	0%	0%	-52.92%	-100%	-	-61.32%	2652.72%	-97.33%

Revenue by Segment

	2014	2015	2016	2018	2019	2021	2022	2023	2024
License and Service	-	-	-	-	-	-	103K	139.1M	3.75M
License and Service Growth	-	-	-	-	-	-	-	134945.63%	-97.31%
Product	-	-	-	-	-	1.11M	4.99M	1.04M	-
Product Growth	-	-	-	-	-	-	348.16%	-79.07%	-
License And Service	-	-	-	300K	100K	12.05M	-	-	-
License And Service Growth	-	-	-	-	-66.67%	11950.00%	-	-	-

Revenue by Geography

	2014	2015	2016	2018	2019	2021	2022	2023	2024
Other Non-US	1.37M	257K	257K	-	-	-	-	-	-
Other Non-US Growth	-	-81.20%	0.00%	-	-	-	-	-	-
UNITED STATES	16.42M	6.93M	-	-	-	-	-	-	-
UNITED STATES Growth	-	-57.79%	-	-	-	-	-	-	-
Europe	1.24M	477K	-	-	-	-	-	-	-
Europe Growth	-	-61.38%	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

SCYNEXIS, Inc. (SCYX) reported $2.9M in revenue for fiscal year 2024. This represents a 83% decrease from $16.8M in 2012.

SCYNEXIS, Inc. (SCYX) saw revenue decline by 97.3% over the past year.

SCYNEXIS, Inc. (SCYX) reported a net loss of $25.3M for fiscal year 2024.

Dividend & Returns

SCYNEXIS, Inc. (SCYX) has a return on equity (ROE) of -33.3%. Negative ROE indicates the company is unprofitable.

SCYNEXIS, Inc. (SCYX) had negative free cash flow of $33.6M in fiscal year 2024, likely due to heavy capital investments.